$34.30
3.29% today
Nasdaq, Apr 03, 06:45 pm CET
ISIN
US68213N1090
Symbol
OMCL

Omnicell, Inc. Stock price

$35.46
-2.27 6.02% 1M
-6.84 16.17% 6M
-9.06 20.35% YTD
+7.71 27.78% 1Y
-91.54 72.08% 3Y
-31.85 47.32% 5Y
+0.54 1.55% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.20 0.57%
ISIN
US68213N1090
Symbol
OMCL
Sector
Industry

Key metrics

Market capitalization $1.66b
Enterprise Value $1.64b
P/E (TTM) P/E ratio 135.19
EV/FCF (TTM) EV/FCF 10.86
EV/Sales (TTM) EV/Sales 1.48
P/S ratio (TTM) P/S ratio 1.49
P/B ratio (TTM) P/B ratio 1.32
Revenue growth (TTM) Revenue growth -3.04%
Revenue (TTM) Revenue $1.11b
EBIT (operating result TTM) EBIT $5.49m
Free Cash Flow (TTM) Free Cash Flow $151.26m
Cash position $398.61m
EPS (TTM) EPS $0.26
P/E forward 56.89
P/S forward 1.46
EV/Sales forward 1.45
Short interest 5.02%
Show more

Is Omnicell, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Omnicell, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Omnicell, Inc. forecast:

4x Buy
44%
5x Hold
56%

Analyst Opinions

9 Analysts have issued a Omnicell, Inc. forecast:

Buy
44%
Hold
56%

Financial data from Omnicell, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,112 1,112
3% 3%
100%
- Direct Costs 637 637
2% 2%
57%
476 476
5% 5%
43%
- Selling and Administrative Expenses 290 290
16% 16%
26%
- Research and Development Expense 90 90
4% 4%
8%
95 95
39% 39%
9%
- Depreciation and Amortization 90 90
46% 46%
8%
EBIT (Operating Income) EBIT 5.49 5.49
148% 148%
0%
Net Profit 13 13
162% 162%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Omnicell, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Omnicell, Inc. Stock News

Neutral
Business Wire
10 days ago
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer.
Neutral
Business Wire
22 days ago
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Chief Financial Officer Transition.
Positive
Seeking Alpha
about 2 months ago
Omnicell's Q4 2024 earnings showed strong service revenue growth, despite soft overall revenue guidance, highlighting the service business as the key value driver. My updated DCF analysis yields a price target of $64.05, representing a 54% upside, and I raise my rating from buy to strong buy. The service business has grown from 6% to 22% of revenue since 2020, outpacing industry growth and impr...
More Omnicell, Inc. News

Company Profile

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.

Head office United States
CEO Randall Lipps
Employees 3,670
Founded 1992
Website www.omnicell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today